Pear

The new tool will be released for limited distribution and will provide multimodal neurobehavioral interventions. 

Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces. 

The industry is better off viewing the the floundering deals between Onduo and Sanofi, Proteus and Otsuka, and Pear and Sandoz as a learning opportunity.

Pharma companies also continued to explore the promises of digital therapeutics. 

The latest funding was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Partners, The Bridge Builders Collaborative and EDBI. 

As the first prescription digital therapeutic approved by the FDA, the treatment will be distributed and supported by a specialist-staffed service center.

The report suggests technology could help address variability in care and boost addiction treatment enrollment. 

The road to FDA clearance for medical devices may change radically in the next year.